08:00 , Nov 5, 2012 |  BC Week In Review  |  Company News

Agenix, Tyrian deal

Agenix received exclusive, worldwide, royalty-free rights to Tyrian's DianostIQ rapid point-of-care technology for human health applications. As part of the deal, Agenix will also acquire a patent from Tyrian covering a biomarker that can differentiate...
07:00 , Jul 9, 2012 |  BC Week In Review  |  Company News

Agenix management update

Agenix Ltd. (ASX:AGX), Melbourne, Australia   Business: Infectious, Diagnostic   Hired: Paul Resnick as senior business advisor, formerly VP of business development at Intellikine Inc., which Takeda Pharmaceuticals Co. Ltd. acquired   ...
07:00 , Oct 24, 2011 |  BC Week In Review  |  Company News

Agenix, Chinese Academy of Medical Sciences, Chinese Institute of Pharmacology and Toxicology of the Academy of Military Medical Sciences deal

Agenix signed a memorandum of understanding with the academy's Institute of Medicinal Biotechnology to develop drug candidates to treat cancer and infectious diseases and share IP, production, marketing and distribution rights. Agenix will gain access...
07:00 , Aug 15, 2005 |  BC Week In Review  |  Company News

Agenix, Akzo Nobel NV deal

AKZ's Diosynth Biotechnology unit will manufacture AGX's ThromboView for Phase III trials and commercial sales. The radiolabeled monoclonal antibody is in Phase II testing as an imaging agent to detect blood clots in patients with...
07:00 , May 16, 2005 |  BioCentury  |  Finance

Taking the ADR route

Taking the ADR route Company Exchange Symbol Country Depositary bank (A) Date Solbec OTC SLBPY Australia BNY 4/18/05 pSivida NASD PSDV Australia CIT 1/27/05 Antisense Therapeutics OTC ATHJY Australia BNY 1/10/05 Regenera OTC RGNFY...
08:00 , Dec 8, 2003 |  BC Week In Review  |  Company News

Agenix, Biosite deal

Agenix Ltd. (ASX:AGX; AGXLY), Brisbane, Australia   Biosite Inc. (BSTE), San Diego, Calif.   Business: Diagnostic   The companies will incorporate AGX's 3B6 antibody for D-dimer into BSTE's Triage Profiler S.O.B. Panel to identify causes of shortness of...
08:00 , Nov 26, 2003 |  BC Extra  |  Company News

Agenix, Biosite diagnostic deal

BSTE partnered with Agenix (ASX:AGX; AGXLY) to incorporate AGX's 3B6 antibody for D-dimer into BSTE's Triage Profiler S.O.B. Panel to identify the cause of shortness of breath. Under the deal, AGX will license D-dimer to...
07:00 , Sep 22, 2003 |  BC Week In Review  |  Clinical News

ThromboView: Phase Ib

In an Australian Phase Ib trial, there were no safety issues and the images obtained were of high quality. Images were obtained from 6 patients who received ThromboView at the first dose level. AGX said...
07:00 , Jul 14, 2003 |  BC Week In Review  |  Clinical News

ThromboView: Phase Ib

In an ongoing open-label Australian Phase Ib trial in 32 patients, ThromboView detected deep vein thrombosis in 1 patient. Agenix Ltd. (ASX:AGX; AGXLY), Brisbane, Australia   Product: ThromboView   Business: Diagnostics/Imaging   Molecular target: NA   Description: Clot-binding monoclonal...
07:00 , Jul 14, 2003 |  BC Week In Review  |  Clinical News

ThromboView: Phase Ia

In an open-label Australian Phase Ia trial in 32 healthy volunteers, ThromboView was well tolerated. Agenix Ltd. (ASX:AGX; AGXLY), Brisbane, Australia   Business: Diagnostics/Imaging   Product: ThromboView   Description: Clot-binding monoclonal antibody attached to a radiolabel   Molecular target:...